Tzu Cancer Therapeutics completed the acquisition of Fetch.

Tzu Cancer Therapeutics, a biotechnology startup, completed the acquisition of Fetch, a creator of a new approach for the separation of cancer cells from white blood cells. Financial terms were not disclosed. “We are excited to team up with the Fetch team and use their unique approach of isolation of circulating tumor cells as a basis for our TzuPlus pipeline. We strongly believe that careful characterization of circulating tumor cells is a key step towards development of next generation personalized cancer therapies," Wigard Kloosterman, Tzu Cancer Therapeutics CEO.